Oral TNFα modulation alters neutrophil infiltration, improves cognition and diminishes tau and amyloid pathology in the 3xtgad mouse model

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Prasad Gabbita, S ^a   Johnson, Ming F ^a   Kobritz, Naomi ^b   Eslami, Pirooz ^b   Poteshkina, Aleksandra ^c   Varadarajan, Sridhar ^c   Turman, John ^a   Zemlan, Frank ^d   Harris White, Marni E ^d  

^a P2D Inc   (United States)

^b UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; ISOINDOLIN 1,3 DITHIONE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ISOINDOLE DERIVATIVE; ISOINDOLIN-1,3-DITHIONE; THIOAMIDE; THIOKETONE; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEARNING; LOW DRUG DOSE; MALE; MEMORY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BRAIN; C57BL MOUSE; CELL LINE; CHEMISTRY; CLASSIFICATION; COGNITION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; MICROGLIA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHENOTYPE; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; SAFETY; SOLUBILITY; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CELL LINE; COGNITION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNITY, INNATE; ISOINDOLES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; NEUTROPHIL INFILTRATION; PHENOTYPE; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; SAFETY; SOLUBILITY; TAU PROTEINS; THIOAMIDES; THIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84947228665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137305     Document Type: Article

References (62)

1. Ling EA (1978) Brain macrophages in rats following intravenous labelling of mononuclear leucocytes with colloidal carbon. J Anat 125: 101-106.
2. Lawson LJ, Perry VH, Gordon S (1992) Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48: 405-415.
3. Lynch MA (2014) The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology 141: 292-301. doi: 10.1111/imm.12156
4. Kwak M, Kim DJ, Lee MR, Wu Y, Han L, Lee SK, et al. (2014) Nanowire array chips for molecular typing of rare trafficking leukocytes with application to neurodegenerative pathology. Nanoscale 6: 6537-6550. doi: 10.1039/c3nr06465d
5. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49: 489-502. doi: 10. 1016/j.neuron.2006.01.022
6. Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, et al. (2012) Early intervention with a small molecule inhibitor for tumor necrosis factor-Alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation 9: 99. doi: 10.1186/1742-2094-9-99
7. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13: 432-438. doi: 10.1038/nm1555
8. Weekman EM, Sudduth TL, Abner EL, Popa GJ, Mendenhall MD, Brothers HM, et al. (2014) Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice. J Neuroinflammation 11: 127. doi: 10.1186/1742-2094-11-127
9. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, et al. (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14: 681-687. doi: 10.1038/nm1781
10. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41: 14-20. doi: 10.1016/j. immuni.2014.06.008
11. Shechter R, Schwartz M (2013) Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how'. J Pathol 229: 332-346. doi: 10.1002/path.4106
12. McAlpine FE, Tansey MG (2008) Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res 1: 29-39.
13. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421.
14. Sharma S, Rakoczy S, Brown-Borg H (2010) Assessment of spatial memory in mice. Life Sci 87: 521-536. doi: 10.1016/j.lfs.2010.09.004
15. Filali M, Lalonde R (2009) Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 1292: 93-99. doi: 10.1016/j.brainres.2009.07.066
16. Deacon RM (2006) Assessing nest building in mice. Nat Protoc 1: 1117-1119. doi: 10.1038/nprot. 2006.170
17. Ly PT, Cai F, SongW(2011) Detection of neuritic plaques in Alzheimer's disease mouse model. J Vis Exp. doi: 10.3791/2831
18. Lauritzen I, Pardossi-Piquard R, Bauer C, Brigham E, Abraham JD, Ranaldi S, et al. (2012) The betasecretase-derived C-terminal fragment of betaAPP, C99, but not Abeta, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci 32: 16243-16255a. doi: 10. 1523/JNEUROSCI.2775-12.2012
19. Spagnuolo C, Cerella C, Russo M, Chateauvieux S, Diederich M, Russo GL (2011) Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br J Cancer 105: 221-230. doi: 10. 1038/bjc.2011.229
20. Xie Z, Harris-White ME, Wals PA, Frautschy SA, Finch CE, Morgan TE (2005) Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. J Neurochem 93: 1038-1046. doi: 10.1111/j.1471-4159.2005.03065.x
21. Henn A, Lund S, Hedtjarn M, Schrattenholz A, Porzgen P, Leist M (2009) The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 26: 83-94.
22. Zhu X, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri DK, et al. (2003) Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-Alpha inhibitory activity. J Med Chem 46: 5222-5229. doi: 10.1021/jm030152f
23. Ohno K, Pettigrew KD, Rapoport SI (1978) Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235: H299-307.
24. Deacon RM, Bannerman DM, Kirby BP, Croucher A, Rawlins JN (2002) Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav Brain Res 133: 57-68.
25. Antonawich FJ, Melton CS, Wu P, Davis JN (1997) Nesting and shredding behavior as an indicator of hippocampal ischemic damage. Brain Res 764: 249-252.
26. Glickman SE, Higgins TJ, Isaacson RL (1970) Some effects of hippocampal lesions on the behavior of Mongolian gerbils. Physiol Behav 5: 931-938.
27. Kim C (1960) Nest building, general activity, and salt preference of rats following hippocampal ablation. J Comp Physiol Psychol 53: 11-16.
28. Kimble DP, Rogers L, Hendrickson CW(1967) Hippocampal lesions disrupt maternal, not sexual, behavior in the albino rat. J Comp Physiol Psychol 63: 401-407.
29. Oh KJ, Perez SE, Lagalwar S, Vana L, Binder L, Mufson EJ (2010) Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int J Alzheimers Dis 2010. doi: 10. 4061/2010/780102
30. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.
31. Jiang H, He P, Xie J, Staufenbiel M, Li R, Shen Y (2014) Genetic deletion of TNFRII gene enhances the Alzheimer-like pathology in an APP transgenic mouse model via reduction of phosphorylated Ikappa-Balpha. Hum Mol Genet 23: 4906-4918. doi: 10.1093/hmg/ddu206
32. Cheng X, He P, Lee T, Yao H, Li R, Shen Y (2014) High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol 184: 141-147. doi: 10.1016/j.ajpath.2013.10.002
33. He P, Cheng X, Staufenbiel M, Li R, Shen Y (2013) Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of beta-secretase in a mouse model of Alzheimer's disease. PLoS One 8: e55091. doi: 10.1371/journal.pone.0055091
34. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, et al. (2007) Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178: 829-841. doi: 10.1083/jcb.200705042
35. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103: 26-35.
36. Porzig R, Singer D, Hoffmann R (2007) Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun 358: 644-649. doi: 10.1016/j.bbrc.2007.04.187
37. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-A brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2: a006346. doi: 10.1101/cshperspect.a006346
38. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K (2003) Cerebral pattern of proand anti-inflammatory cytokines in dementias. Brain Res Bull 61: 255-260.
39. Tarkowski E, Andreasen N, Tarkowski A, B K. (2003) Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 1200-1205.
40. Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol 50: 534-544. doi: 10. 1007/s12035-014-8657-1
41. Guerreiro RJ, Santana I, Bras JM, Santiago B, Paiva A, Oliveira C (2007) Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener Dis 4: 406-412. doi: 10.1159/000107700
42. Montgomery SL, Mastrangelo MA, Habib D, Narrow WC, Knowlden SA, Wright TW, et al. (2011) Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology implications for chronic pan-TNF-Alpha suppressive therapeutic strategies in the brain. Am J Pathol 179: 2053-2070. doi: 10.1016/j.ajpath.2011.07.001
43. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, et al. (2011) Anti-TNF-Alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 1368: 239-247. doi: 10.1016/j.brainres.2010.10.053
44. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5: 45. doi: 10.1186/1742-2094-5-45
45. Giuliani F, Vernay A, Leuba G, Schenk F (2009) Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-Alpha metabolism. Brain Res Bull 80: 302-308. doi: 10.1016/j. brainresbull.2009.07.009
46. Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, et al. (2012) Tumor necrosis factor-Alpha synthesis inhibitor 3, 6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation 9: 106. doi: 10.1186/1742-2094-9-106
47. Scheinfeld N (2004) A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15: 280-294. doi: 10. 1080/09546630410017275
48. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48: 319-324. doi: 10.1002/art.10758
49. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261-1265. doi: 10.1086/383317
50. Wallis RS, Broder M, Wong J, Beenhouwer D (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39: 1254-1255. doi: 10.1086/424455
51. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-Analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285. doi: 10. 1001/jama.295.19.2275
52. Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, et al. (2012) Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 15: 77-90. doi: 10.1017/S1461145711000149
53. Koenigsknecht-Talboo J, Landreth GE (2005) Microglial phagocytosis induced by fibrillar beta-Amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 25: 8240-8249. doi: 10. 1523/JNEUROSCI.1808-05.2005
54. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, et al. (2010) IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 184: 5333-5343. doi: 10.4049/jimmunol.0903382
55. Wilcock DM, Zhao Q, Morgan D, Gordon MN, Everhart A, Wilson JG, et al. (2011) Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro 3: 249-258. doi: 10.1042/AN20110018
56. Jaremo P, Milovanovic M, Buller C, Nilsson S, Winblad B (2013) Alzheimer's disease and granulocyte density diversity. Eur J Clin Invest 43: 545-548. doi: 10.1111/eci.12072
57. Davydova TV, Fomina VG, Voskresenskaya NI, Doronina OA (2003) Phagocytic activity and state of bactericidal systems in polymorphonuclear leukocytes from patients with Alzheimer's disease. Bull Exp Biol Med 136: 355-357. doi: 10.1023/B:BEBM.0000010950.53560.e2
58. Smith E, Zarbock A, Stark MA, Burcin TL, Bruce AC, Foley P, et al. (2007) IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice. J Immunol 179: 8274-8279.
59. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A (2013) Neutrophils in innate and adaptive immunity. Semin Immunopathol 35: 377-394. doi: 10.1007/s00281-013-0374-8
60. Dinkel K, Dhabhar FS, Sapolsky RM (2004) Neurotoxic effects of polymorphonuclear granulocytes on hippocampal primary cultures. Proc Natl Acad Sci U S A 101: 331-336. doi: 10.1073/pnas. 0303510101
61. Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11: 519-531. doi: 10.1038/nri3024
62. Zheng X, Zhang X, Kang A, Ran C, Wang G, Hao H (2015) Thinking outside the brain for cognitive improvement: Is peripheral immunomodulation on the way? Neuropharmacology 96: 94-104. doi: 10. 1016/j.neuropharm.2014.06.020 PMID: 24978103.